Skip to content
FDA Import Alert · 66-41

Similasan AG · Jonen, SWITZERLAND

Listed 2023-09-12 · 10 product codes · Source: FDA Import Alert 66-41 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Similasan AG

7 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2023-09-12 ~ 2026-11-12

Areas cited

Laboratory and QC controlsProcess validationAseptic processing and sterility assuranceEquipment and facility

Published inspection documents

Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. (21 CFR 211.194(a)) Your laboratory records do not include complete testing data to support the analysis performed. For example, negative controls for sterility testing are not documented at the time of performance. The absence of concurrently performed negative controls during sterility testing does not allow full assessment of the suitability of the testing performed. All CGMP-related data must be retained to enable appropriate assessments and decisions by the QU and to demonstrate ongoing control. The lack of complete testing records compromises the integrity of the testing results. In your response, you state that you will implement new test method records for standard preparations. You also state that you will follow your test procedures in accordance with the compendial method, and finished product test results reported by the quality control unit for sterile drug products will be accurately recorded. Your response is inadequate because there is no commitment to conduct retrospective reviews for tested products and training of employees to correct deficient practices. In response to this letter, provide: • A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation. • Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls. 2023-09-12 US FDA 4 findingsAseptic processing and sterility assurance · Laboratory and QC controls View the regulator's official source

21 CFR sections cited in FDA inspections

Citations from 1 FDA inspection (2026-04-27) of facilities listed under this company name in FDA's inspection citation data.

As written by FDAInspectionLatest inspection
21 CFR 211.100(a)Absence of Written Procedures12026-04-27
21 CFR 211.160(b)(1)Incoming lots - conformance to written specs-12026-04-27
21 CFR 211.68(a)Calibration/Inspection/Checking not done12026-04-27

1 site: Similasan AG (Jonen, Switzerland) · 1 inspection

Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Similasan AG — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.